Featured New Member

Lee J. Helman, M.D. 
Professor of Pediatrics and Medicine, Keck School of Medicine, USC Head, Basic and Translational Research
Children’s Center for Cancer and Blood Diseases Children’s Hospital of Los Angeles
Director, Cancer Research Program

Bio

Lee J. Helman received his M.D. from the University of Maryland School of Medicine magna cum laude and was elected to Alpha Omega Alpha. He completed his internship and residency in internal medicine at Barnes Hospital, Washington University. Dr. Helman completed training in medical oncology at the National Cancer Institute (NCI). He did his post-doctoral training in the Molecular Genetics Section, Pediatric Branch, NCI, and then became Head of the Molecular Oncology Section, Pediatric Oncology Branch, NCI. He served as Chief of the Pediatric Oncology Branch from 1997- 2007 and as Scientific Director for Clinical Research in the Center for Cancer Research, NCI, from 2007 to 2016. He joined Children’s Hospital Los Angeles (CHLA) and the University of Southern California (USC) in 2017 as professor of Pediatrics and Medicine at the Keck School of Medicine and director of Basic and Translational Research within the Children’s Center for Cancer and Blood Diseases at CHLA and is a member of the USC Norris Comprehensive Cancer Center. He was elected to the American Society for Clinical Investigation and the American Association of Physicians and is a founding member and past president of the Connective Tissue Oncology Society. He received the 2011 ASCO Pediatric Oncology Award and is a Fellow of ASCO. Dr. Helman was the inaugural chair of the Pediatric Oncology Working Group of AACR. He serves as a vice chair of the Scientific Advisory Committee of Stand Up To Cancer, a scientific partner to the AACR. Dr. Helman’s laboratory work focuses on the biology and treatment of rhabdomyosarcoma, Ewing’s sarcoma, osteosarcoma, and pediatric GIST tumors. Major areas of research include the pathophysiologic consequences of IGF signaling, identification of the molecular/biochemical determinants of the biology of sarcomas, and the application of functional genomics to identify new treatment targets.